Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twelve analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and eleven have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $41.00.
Several brokerages have recently issued reports on VRDN. Wall Street Zen raised shares of Viridian Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Saturday, November 7th. Needham & Company LLC boosted their price target on Viridian Therapeutics from $34.00 to $38.00 and gave the company a "buy" rating in a research report on Wednesday, November 4th. HC Wainwright upped their price target on Viridian Therapeutics from $22.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, November 5th. Truist Financial raised their price objective on Viridian Therapeutics from $39.00 to $42.00 and gave the stock a "buy" rating in a report on Thursday, November 5th. Finally, Royal Bank Of Canada boosted their target price on Viridian Therapeutics from $38.00 to $41.00 and gave the stock an "outperform" rating in a report on Thursday, November 5th.
Get Our Latest Stock Analysis on Viridian Therapeutics
Viridian Therapeutics Trading Up 0.2%
Shares of Viridian Therapeutics stock opened at $30.12 on Thursday. Viridian Therapeutics has a fifty-two week low of $13.18 and a fifty-two week high of $34.29. The business's fifty day moving average is $23.17 and its two-hundred day moving average is $21.70. The company has a quick ratio of 14.46, a current ratio of 14.46 and a debt-to-equity ratio of 0.50. The firm has a market cap of $3.42 billion, a PE ratio of -7.84 and a beta of 1.07.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($1.02) by $0.21. Viridian Therapeutics had a negative return on equity of 79.67% and a negative net margin of 1,620.79%. The business had revenue of $25.75 million during the quarter, compared to the consensus estimate of $4.72 million. Analysts anticipate that Viridian Therapeutics will post -3.64 earnings per share for the current year.
Institutional Investors Weigh In On Viridian Therapeutics
Several institutional investors have recently bought and sold shares of VRDN. KBC Group NV purchased a new stake in Viridian Therapeutics during the 1st quarter worth $34,000. Integrated Wealth Concepts LLC purchased a new position in Viridian Therapeutics in the 2nd quarter valued at about $33,000. State of Wyoming acquired a new stake in shares of Viridian Therapeutics during the second quarter valued at about $43,000. Fulcrum Asset Management LLP acquired a new stake in Viridian Therapeutics during the 3rd quarter valued at approximately $97,000. Finally, AlphaCentric Advisors LLC purchased a new stake in Viridian Therapeutics during the 3rd quarter worth approximately $216,000.
About Viridian Therapeutics
(
Get Free Report)
Viridian Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes. The company's pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.